Galapagos Genomics

Galapagos Genomics NV is a biotech company located in Mechelen, Belgium. The company was founded in 1999 as a joint venture between Crucell (formerly IntroGene) and Tibotec. The company has its own internal discovery programs which it combines with drug discovery and pre-clinical service activities for other biotech and pharmaceutical companies. Onno van de Stolpe is the CEO of the company.

Additional recommended knowledge

Don't let static charges disrupt your weighing accuracy

Daily Sensitivity Test

Correct Test Weight Handling Guide: 12 Practical Tips

The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins.

References

• Edwards PJ., The impact of parallel chemistry in drug discovery, IDrugs. 2006 May;9(5):347-53.

See also

• FlandersBio

Source

• Galapagos Genomics gaat zelf medicijnen ontwikkelen (Dutch)
• Een rotsvast geloof in de Vlaamse biotech